<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00038415</url>
  </required_header>
  <id_info>
    <org_study_id>DM99-412</org_study_id>
    <nct_id>NCT00038415</nct_id>
  </id_info>
  <brief_title>A Phase I/II Trial of Idiotypic Vaccination for Chronic Lymphocytic Leukemia Using a Genetic Approach</brief_title>
  <official_title>A Phase I/II Trial of Idiotypic Vaccination for Chronic Lymphocytic Leukemia Using a Genetic Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is learn if a vaccine that contains the patient's&#xD;
      own cancer cell immunoglobulin can shrink or slow the growth of Chronic Lymphocytic Leukemia&#xD;
      (CLL). This clinical trial is a dose escalation study in which the safety of this vaccine&#xD;
      will be studied. This is a dose escalation study in which each patient will receive vaccine&#xD;
      at one dose level. Patients will be injected with a fragment of Deoxyribonucleic acid (DNA)&#xD;
      containing the sequence of their own immunoglobulin gene. Patients will be required to have&#xD;
      their diagnosis of CLL and stage confirmed prior to initiating vaccination. After vaccination&#xD;
      patients will receive clinical and immunologic evaluation, including both humoral and&#xD;
      cellular responses. The investigator will be assessing the patient's immune response or&#xD;
      whether the patient's body recognizes the DNA vaccine. In addition, side effects and&#xD;
      reactions to the vaccine will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        1. To determine if patients with Binet Stage A CLL generate an immune response to an&#xD;
           antigen delivered by a DNA vaccine.&#xD;
&#xD;
        2. To determine if patients with Binet Stage A CLL generate an immune response to a tumor&#xD;
           derived antigen delivered by a DNA vaccine.&#xD;
&#xD;
        3. To determine the optimal dose of DNA vaccine to obtain anti-idiotype immune responses.&#xD;
&#xD;
        4. To characterize any adverse effects of idiotypic vaccination with a DNA vaccine.&#xD;
&#xD;
        5. To determine if DNA idiotypic vaccination is capable of inducing remission in BinetÂ´s&#xD;
           Stage A CLL.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Vaccine unavailable.&#xD;
  </why_stopped>
  <start_date>December 2001</start_date>
  <completion_date type="Actual">January 2005</completion_date>
  <primary_completion_date type="Actual">July 2004</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Continuous reassessment up to 1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Leukemia, Lymphocytic, Chronic</condition>
  <arm_group>
    <arm_group_label>Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CLL vaccine using DNA plasmid vector</intervention_name>
    <arm_group_label>Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with Binet Stage A Chronic Lymphocytic Leukemia (CLL)&#xD;
&#xD;
          -  WHO performance status of 2 or less.&#xD;
&#xD;
          -  A life expectancy of at least one year.&#xD;
&#xD;
          -  Greater than 18 years of age.&#xD;
&#xD;
          -  Availability of CLL cells which can be used for DNA extraction and processing.&#xD;
&#xD;
          -  A platelet count greater than 100 x 109/l.&#xD;
&#xD;
          -  Ability to provide full informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous chemotherapy or radiotherapy.&#xD;
&#xD;
          -  Presence of a monoclonal band on serum electrophoresis.&#xD;
&#xD;
          -  Presence of clinically significant levels of anti-DNA antibodies, anti-muscle&#xD;
             antibodies or rheumatoid factors or who have active autoimmune disease.&#xD;
&#xD;
          -  Presence of antibodies to human immunodeficiency virus (HIV) and known carriers of&#xD;
             hepatitis B or hepatitis C virus.&#xD;
&#xD;
          -  Presence of other serious medical condition e.g. congestive heart failure.&#xD;
&#xD;
          -  Presence of other malignancies.&#xD;
&#xD;
          -  Pregnancy, lactation, or not using contraceptive measures.&#xD;
&#xD;
          -  Concurrent use of other anti-cancer therapy.&#xD;
&#xD;
          -  Patients allergic to tetanus vaccine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael J. Keating, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT MD Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>May 30, 2002</study_first_submitted>
  <study_first_submitted_qc>May 30, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2002</study_first_posted>
  <last_update_submitted>October 30, 2018</last_update_submitted>
  <last_update_submitted_qc>October 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>CLL</keyword>
  <keyword>Binet Stage A</keyword>
  <keyword>Vaccination</keyword>
  <keyword>Idiotypic</keyword>
  <keyword>Genetic</keyword>
  <keyword>Deoxyribonucleic acid</keyword>
  <keyword>DNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

